Why is Aurobindo Pharma Ltd. ?
1
Company has a low Debt to Equity ratio (avg) at 0.01 times
2
Poor long term growth as Operating profit has grown by an annual rate 7.38% of over the last 5 years
3
Positive results in Sep 26
- NET SALES(Q) Highest at Rs 10,263.29 cr
- OPERATING PROFIT TO INTEREST(Q) Highest at 21.09 times
- CASH AND CASH EQUIVALENTS(HY) Highest at Rs 9,949.27 cr
4
Stock is technically in a Bullish range
- The technical trend has improved from Mildly Bullish on 30-Oct-26 and has generated 7% returns since then
- Multiple factors for the stock are Bullish like MACD, Bollinger Band, KST, DOW and OBV
5
With ROE of 10.3, it has a Fair valuation with a 2.6 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 48.57%, its profits have risen by 18.7% ; the PEG ratio of the company is 1.2
6
High Institutional Holdings at 41.83%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
How much should you hold?
- Overall Portfolio exposure to Aurobindo Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Aurobindo Pharma for you?
Medium Risk, High Return
Absolute
Risk Adjusted
Volatility
Aurobindo Pharma
48.57%
1.84
26.43%
Sensex
-2.0%
-0.13
14.98%
Quality key factors
Factor
Value
Sales Growth (5y)
8.98%
EBIT Growth (5y)
7.38%
EBIT to Interest (avg)
18.34
Debt to EBITDA (avg)
1.20
Net Debt to Equity (avg)
-0.03
Sales to Capital Employed (avg)
0.78
Tax Ratio
31.64%
Dividend Payout Ratio
0
Pledged Shares
11.99%
Institutional Holding
41.83%
ROCE (avg)
13.36%
ROE (avg)
9.86%
Valuation Key Factors 
Factor
Value
P/E Ratio
25
Industry P/E
40
Price to Book Value
2.62
EV to EBIT
18.20
EV to EBITDA
13.48
EV to Capital Employed
2.68
EV to Sales
2.76
PEG Ratio
1.22
Dividend Yield
0.39%
ROCE (Latest)
14.72%
ROE (Latest)
10.31%
Loading Valuation Snapshot...
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Bullish
Bullish
OBV
Bullish
Bullish
Technical Movement
18What is working for the Company
NET SALES(Q)
Highest at Rs 10,263.29 cr
OPERATING PROFIT TO INTEREST(Q)
Highest at 21.09 times
CASH AND CASH EQUIVALENTS(HY)
Highest at Rs 9,949.27 cr
PBDIT(Q)
Highest at Rs 2,155.75 cr.
OPERATING PROFIT TO NET SALES(Q)
Highest at 21.00%
PBT LESS OI(Q)
Highest at Rs 1,519.45 cr.
PAT(Q)
Highest at Rs 1,126.08 cr.
EPS(Q)
Highest at Rs 19.57
-1What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Aurobindo Pharma
Net Sales - Quarterly
Highest at Rs 10,263.29 cr and Grown
each quarter in the last five quartersMOJO Watch
Near term sales trend is very positive
Net Sales (Rs Cr)
Operating Profit to Interest - Quarterly
Highest at 21.09 times
in the last five quartersMOJO Watch
The company's ability to manage interest payments is improving
Operating Profit to Interest
Operating Profit (PBDIT) - Quarterly
Highest at Rs 2,155.75 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Operating Profit Margin - Quarterly
Highest at 21.00%
in the last five quartersMOJO Watch
Company's efficiency has improved
Operating Profit to Sales
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 1,519.45 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 1,519.45 cr has Grown at 25.7% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 1,209.04 CrMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 1,126.08 cr.
in the last five quartersMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Earnings per Share (EPS) - Quarterly
Highest at Rs 19.57
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
Cash and Cash Equivalents - Half Yearly
Highest at Rs 9,949.27 cr
in the last six half yearly periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents